Literature DB >> 5046104

Species differences in the biotransformation of a new antiarrhythmic agent: disopyramide phosphate.

A Karim, R E Ranney, S Kraychy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 5046104     DOI： 10.1002/jps.2600610612

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN： 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  7 in total

1.  Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans.

Authors:  P H Hinderling; E R Garrett
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

Review 2.  Clinical pharmacokinetics of disopyramide.

Authors:  A Karim; C Nissen; D L Azarnoff
Journal:  J Pharmacokinet Biopharm       Date:  1982-10

3.  Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.

Authors:  S M Bryson; B Whiting; J R Lawrence
Journal:  Br J Clin Pharmacol       Date:  1978-11       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of disopyramide.

Authors:  L A Siddoway; R L Woosley
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

5.  The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.

Authors:  K M Giacomini; S E Swezey; K Turner-Tamiyasu; T F Blaschke
Journal:  J Pharmacokinet Biopharm       Date:  1982-02

6.  Effects of the enantiomers of disopyramide and its major metabolite on the electrophysiological characteristics of the guinea-pig papillary muscle.

Authors:  F Vanhoutte; J Vereecke; E Carmeliet; N Verbeke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-12       Impact factor: 3.000

7.  In vitro Metabolism of Bumetanide.

Authors:  G Grosa; F Viola; O Caputo; G Biglino
Journal:  Pharm Res       Date:  1984-11       Impact factor: 4.200
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.